OCC Trading, page-1016

HOtdog,

Its getting a bit old. You (and all of us) have discussed the management failures to death on here. Some of us have politely, but sternly pushed them on shortcomings and accordingly the information flows in the Appendix 4C's are now far more informative and adherence to timescales improved.

How have management not added value for years?

I am not defeneding them, but last time I checked they recently added TGA and FDA approval for CelGro Bone (Striate) to its EMA approval. They've gotten TGA approval for CelGro Nerve (Remplir). They've 24 month Remplir studies with 85% functional recovery of muscles controlled by the repaired nerve and restoring upper limb function in a quadriplegic patient cohort, with 92% functional recovery (MRC ≥3) of muscles controlled by the repaired nerve at 12 months,....and impressive results in ATI in 12 month studies with 95% success in patients who had an average of 4 failed conservative treatments including physiotherapy and steroid injections.

What they have been poor at, is commercialisation of these impressive trial and regulatory results. They have over-promised and under-delivered on partnerships and commercial return timescales and revenues, though now clearly growing, are still far too low. They need to deliver on partnerships soon and there will be information on that, I am confident, in the next announcements and Appendix 4C - God knows I've personally politely, but firmly, hammered them enough on the same subject and I know they are sick of me.

Mate you bashed HC investors for a long time on here as having "weak hands". Then you sold out half your holdings yourself. Now you are relentlessly bagging the company on every thread here (this one is about trading) with the same criticisms we all have discussed to death (and some of use have made repetitively clear to the company).